Cancer care: the future is now (6 November 2024)

10 September 2024

Are you curious about what cancer care in Belgium will look like in the future? Then be sure to mark your calendar for November 6, 2024. On this day, All.Can Belgium will host the conference "Cancer Care: The Future is Now," focusing on the oncological (r)evolution in the 21st century and featuring leading medical experts and policymakers.

    During the conference, we will explore the most significant developments in oncology and their impact on patients and their communities, healthcare organizations, and the overall healthcare system.

    We will also address the challenges: What is still required today to effectively deliver valuable oncological innovations to Belgian patients and healthcare organizations? And how can we overcome these obstacles?

    We will do this through panels focused on six topics:

    1. The oncological (r)evolution in the 21st century
    2. The impact of innovation in oncology on healthcare organizations
    3. Clinical research in the era of molecular oncology
    4. Access to innovative treatments
    5. The role of AI in cancer care
    6. Digital technology as a companion for patients and healthcare organizations

    Practical info

    • What? Conference “Cancer care: the future is now”
    • When? Wednesday, 6 November 2024
    • Where? TRACK, Rue du Progrès 76, 1030 Bruxelles

    Admission to the conference is free, but registration is mandatory. Register here.

    More articles

    An abnormal cervical smear. Now what?

    Every year, almost 9,000 women [1] undergo a cone biopsy to treat precancerous lesions. Precancerous lesions are abnormal cells in the cervix that can develop into cervical cancer. They are detected through cervical screening. A cone biopsy is preceded by a colposcopy – a closer examination of the cervix. In…

    “We have what it takes to eliminate cervical cancer”

    Since January 2025, cervical cancer screening for women aged 30 and over has been carried out differently. The smear is now first tested for the presence of human papillomavirus (HPV), and only then, depending on the result of that first test, are the cells examined. There is a good reason…